Cannabis Regulation in Transition

One year of international monitoring, knowledge exchange and practical analysis

Recreational Cannabis Foundation — July 2026

Executive summary

Cannabis policy is undergoing a fundamental but uneven transformation. Cannabis remains the most commonly used illicit drug in Europe, while legal responses now range from prohibition and reduced penalties to home cultivation, non-commercial associations, pilot projects, tolerated retail and nationally regulated commercial markets.

The international debate is therefore no longer limited to whether possession should be punished. Governments increasingly face questions of market design: how legal access should be organised, how consumers should be protected, how illicit supply can be reduced, how existing participants should be treated and how outcomes should be measured.

Europe has not developed one common cannabis model. Instead, it has produced a fragmented landscape of partial reforms. Germany permits private cultivation and non-commercial associations but no general retail market. Malta uses licensed non-profit associations. Luxembourg and Czechia have expanded private-use legality. Switzerland combines scientific pilots with work towards national legislation. The Netherlands is testing regulated production and supply through existing coffeeshops.

Outside Europe, Canada and Uruguay operate national regulated systems, while the United States combines extensive state-level markets with continuing federal complexity. South Africa permits private use without a general lawful commercial supply route. Thailand illustrates the risks of rapid liberalisation before a complete regulatory framework is operational. Australia continues to develop through state and territorial variation.

At-a-glance status overview

This overview summarises the legal status as of 20 July 2026. Market model and procedural phase are separate data points: an adopted act is not automatically operational, and decriminalising possession does not create a legal supply channel. The colour coding reflects solely the availability of a lawful adult-use access channel, not political desirability.

<b>Colour coding.</b> <b>Green</b>: lawful adult-use access channel that is operational (commercial or non-commercial). <b>Amber</b>: partial, experimental or conditional access without a general national supply channel. <b>Red</b>: no lawful adult-use supply channel. <b>Grey</b>: material differences between national and subnational law.

Adult use is defined in this whitepaper as non-medical cannabis use by adults. Cannabis associations are not a separate category alongside commercial sales but one possible form of a regulated adult-use access channel.

Introduction

Cannabis is widely available under almost every legal model. Prohibition has not eliminated production, trade or consumption. Reform does not remove government responsibility; it changes its form. Once possession, cultivation or access is permitted, authorities must make choices about production, distribution, products, age limits, quality, retail, taxation, advertising, monitoring and enforcement.

The central question has shifted from whether cannabis should remain prohibited to which regulatory arrangements can protect public health, reduce illicit activity and function under real market conditions.

This whitepaper has two purposes. First, it records the public work developed during the first year of the Recreational Cannabis Foundation. Second, it provides a comparative analysis of the state of cannabis regulation in Europe and selected jurisdictions worldwide as of 20 July 2026.

The report uses “regulation” broadly to describe legal frameworks governing non-medical adult cannabis. It distinguishes regulation from decriminalisation, depenalisation and tolerance. Those distinctions are essential because possession may be lawful while production and sale remain prohibited.

Purpose and methodology

The Foundation was established to improve access to reliable information about recreational cannabis regulation and to make Dutch practical knowledge accessible in an international context. Its public activities are monitoring, interpretation, documentation and knowledge exchange.

Factual and legal conclusions in this whitepaper rely solely on legislation, official gazettes, parliamentary documents, government and regulator publications, judicial decisions, and official publications of recognised intergovernmental organisations.

Media reports, industry figures, lobbying publications, commercial analyses and unofficial summaries do not constitute evidence of the legal status of a country or measure.

Research commissioned by a government or public institution may be used as evaluative context. Such research is clearly distinguished from binding legislation, policy decisions and operational implementation.

The Foundation's first year

During the first year, the Foundation followed legislative and regulatory developments across Europe, North America, Africa, Asia and Australia. The work included proposed laws, adopted rules, parliamentary inquiries, government responses, court decisions, scientific evaluations, consultations and implementation guidance.

Monitoring was structured around procedural status. Each development was assessed by asking what had changed formally, which authority was responsible, whether further approval was required, when implementation would occur and which questions remained unresolved.

The public updates were regularly linked to original documents. This is important in cannabis policy because media summaries frequently collapse different stages of reform into a single claim that a country has “legalised” cannabis.

Primary-source reporting makes it possible to state more precisely whether a measure concerns personal possession, cultivation, distribution, scientific research, licensed supply, medical access, hemp or product standards.

Europe: a fragmented transition

Cannabis remains Europe's most widely consumed illicit drug and is associated with a large share of drug-law offences. At the same time, national laws increasingly diverge. EUDA now treats cannabis policy as a distinct field of comparative analysis and emphasises that European responses range from criminal prohibition to controlled forms of legal access.

The EU does not operate a common adult-use cannabis market. Criminal law, public health and licensing largely remain national matters, while European rules may still affect agriculture, food, medicines, consumer products, services and cross-border trade.

The Netherlands has tolerated retail sale through coffeeshops for decades while commercial cultivation and wholesale supply remained prohibited. This produced the structural “back-door problem”: the retail outlet could operate under conditions, but its ordinary supply could not be lawfully produced and purchased.

The Controlled Cannabis Supply Chain Experiment tests whether production, distribution and sale of quality-controlled cannabis can be regulated and what effects this has on crime, safety and public health.

Global developments

Cannabis remains the world's most widely used controlled drug. Legal production now coexists with large illicit markets, while national and subnational systems differ sharply in commercialisation, access and public-health controls.

Canada's Cannabis Act entered into force on 17 October 2018 and established a national control framework. Federal law regulates production, products and promotion, while provinces and territories organise distribution and retail.

The 2024 legislative review found that the framework had created a licensed industry, expanded access to quality-controlled products, reduced possession charges and supported movement towards the legal market. It also identified continuing problems concerning illicit-market displacement, Indigenous participation, small businesses, regulatory burden, medical access and research.

Canada demonstrates that a national legal market can capture a large share of demand, but that displacement is gradual and depends on retail access, product range, pricing, taxation and regulatory efficiency.

International legal context

Cannabis remains under international control by virtue of the 1961 Single Convention on Narcotic Drugs. The convention limits production, manufacture, export, import, distribution, trade, use and possession of scheduled substances in principle to medical and scientific purposes. The international drug conventions require states to render certain conduct outside authorised channels criminal, having regard to the convention texts and the national constitutional order. The 2020 change to the international classification reduced the level of international control but did not terminate that control.

The World Health Organization's review led to changes in the international scheduling position of cannabis in 2020, but did not remove cannabis from international control.

Countries have responded to treaty tension in different ways: scientific pilots, cautious non-commercial models, constitutional reasoning, explicit acknowledgment of non-compliance or treaty procedures.

International law has therefore influenced the form and pace of reform, especially in Europe. It has not prevented national experimentation, but it contributes to fragmented and legally cautious models.

Comparative findings

Reducing penalties changes the legal position of the consumer, not necessarily the producer or supplier. Where possession is legal but supply is not, the system remains dependent on home cultivation, informal transfer, tolerated supply or illicit purchase.

A legal channel cannot displace illicit supply if it is geographically limited, administratively burdensome, costly, privacy-sensitive or unable to meet demand.

Consumers distinguish between flower, resin, potency, cultivar, production method and format. A narrow regulated offer may fail to replace an established illicit market. Diversity must nevertheless be balanced against health risks and commercial incentives.

Licensing, construction, cultivation, testing, transport, retail systems and consumer adaptation require time. A rigid transition can create shortages, price increases and renewed illicit demand.

The Dutch experience

The coffeeshop system demonstrates that identifiable retail outlets can separate cannabis consumers from some other illicit drug markets, apply age restrictions, operate under local conditions, provide consumer information and create accountable points of sale.

The separation between tolerated retail and prohibited commercial supply produced persistent problems: no lawful purchasing chain, limited origin transparency, restricted product control, stock constraints, legal vulnerability and continuing dependence on illicit production.

The controlled supply-chain experiment tests whether this structural contradiction can be replaced by regulated production and traceable distribution while retaining existing retail knowledge.

New regulatory systems often devote greater attention to cultivation than to retail. Dutch experience adds evidence about consumer demand, product substitution, hashish, staff training, age verification, local licensing, consumer information and the effects of shortages.

Outlook

Europe is unlikely to adopt one adult-use model in the near future. The more probable direction is continued differentiation: expansion of home cultivation in some countries, non-commercial associations in others, scientific pilots, limited permanent frameworks and continuing prohibition with reduced penalties elsewhere.

The next phase of European debate will focus less on legal principle and more on operational performance: lawful supply, illicit-market displacement, youth protection, regulator capacity, product standards and evaluation.

National commercial systems will continue to produce evidence on legal-market displacement, taxation and public health. Private-use and non-commercial systems will test whether access can function without ordinary retail. Federal systems will continue to expose conflicts between national and regional law.

Lower- and middle-income countries will increasingly face distributional questions: who receives licences, whether traditional growers can enter legal markets, where value is created and whether reform benefits communities previously affected by prohibition.

Priorities for the next phase

Organisational basis and funding

During its first year, the Foundation developed an international knowledge network, a monitoring structure, a growing archive of primary materials and the organisational basis needed for continued public-interest work.

The Foundation has no structural source of income. Its public activities depend on donations and project-based contributions. Funding supports research, monitoring, translation, publications, international knowledge exchange, public conferences and information infrastructure.

The Foundation safeguards the independence of its public work. Donations and project-based contributions do not determine the conclusions of its research, monitoring or publications.

Conclusion

Cannabis regulation has entered a new phase. Governments are no longer dealing only with criminal-law exceptions. They are designing systems of production, distribution, access, health protection, enforcement and evaluation.

No single model resolves every issue. Commercial markets can provide broad access but require strong controls. Non-commercial associations can limit promotional incentives but may have limited capacity. Home cultivation protects private autonomy but cannot serve every consumer. Scientific pilots produce evidence but do not themselves resolve general access. Tolerated retail can reduce some harms while leaving major problems unresolved if supply remains illegal.

The central lesson is that cannabis regulation must be assessed as a complete system. Production, distribution, retail, consumer protection, enforcement, public health and evaluation cannot be designed independently.

By monitoring official developments, comparing regulatory approaches and documenting practical experience, the Recreational Cannabis Foundation aims to contribute to a better-informed international understanding of what regulation requires in practice.

Comparative legal status at a glance

This table is built from the same central data model as the status overview in Chapter 3. The Adult use / recreational column always shows a fixed market-model label in bold with a short legal explanation below. Market model and procedural phase are strictly separated.

Timeline of monitored developments

Chronological overview of the substantive legal, regulatory, research and implementation developments monitored during the Foundation's first year.

Appendix A. Developments monitored during the first year

This appendix provides further detail on the substantive developments listed in the preceding timeline. It covers the Foundation's public monitoring from March 2025 through 20 July 2026.

The government confirmed that the experimental phase would begin on 7 April 2025. Seven licensed growers were expected to supply participating coffeeshops. The official material acknowledged that regulated herbal cannabis was available in sufficient quantities, but that the quality, character and diversity of regulated hashish did not yet match the established market. Five growers were subject to a statutory start requirement: failure to begin production by 6 May 2025 could lead to withdrawal of their designation. The experiment was fixed in legislation for at least four years, with the possibility of an extension of up to eighteen months.

Comparative significance. The update identified product diversity and production capacity as implementation conditions, not secondary commercial concerns. It also showed that a regulated market cannot be assessed separately from the products consumers already use.

A ministerial amendment extended the waiting list of eligible cultivation applicants until 7 April 2027. Keeping it active allowed the government to replace a designated grower without restarting the full selection and lottery procedure. The two-year extension was shorter than an earlier four-year proposal because a grower admitted late in the experiment would have insufficient time to develop a viable operation.

Appendix B. Source map by analytical theme

Prevalence, harms and European market — EUDA European Drug Reports 2025 and 2026; EUDA Cannabis Policy Hub.

International legal obligations — 1961, 1971 and 1988 UN conventions; WHO ECDD reviews; EUDA treaty FAQ.

Tolerated retail and regulated supply — Dutch experiment legislation, official guidance, timeline and parliamentary progress letters.

Private cultivation and associations — Germany KCanG and evaluations; Malta legislation and licensing guidance; Luxembourg 2023 Act; Czech Act 270/2025.

Appendix C. References and primary sources

The references below identify the primary or institutional sources used for the factual statements in this paper. Direct document links, formal titles and document numbers should be used wherever available. General institutional homepages are included only where no stable document-specific link was available at the time of publication. All URLs were accessed on 20 July 2026.

  1. Single Convention on Narcotic Drugs, as amended by the 1972 Protocol — United Nations — 1961/1972
  2. Convention on Psychotropic Substances — United Nations — 1971
  3. Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances — United Nations — 1988
  4. 41st Expert Committee on Drug Dependence — Cannabis and cannabis-related substances (recommendations) — World Health Organization — 24 January 2019 — ECDD/41
  5. European Drug Report 2025 — EUDA (formerly EMCDDA) — 2025
  6. European Drug Report 2026 — EUDA — 2026
  7. New EU Drugs Strategy 2026–2030 and Action Plan against drug trafficking — proposal and Council decisions — European Commission / Council of the EU — Proposal 4 December 2025 · Council decisions 5 March 2026 and 4 June 2026 — COM(2025) proposal · Council conclusions
  8. Proposal on the use of the whole hemp plant in the CAP framework — European Commission — 15 July 2025 — Regulation (EU) 2021/2115, Article 4(4) — 0.3 % THC threshold for industrial hemp; whole-plant clarification proposed 15 July 2025
  9. Cannabis flos herbal monograph — discontinuation notice — European Medicines Agency — 2025 — EMA/HMPC/decision 2025 — Cannabis flos monograph withdrawal
  10. Cannabis flos quality monograph — revision consultation — European Pharmacopoeia (EDQM) — September 2025 – 31 December 2025 — Pharmeuropa 37.3 — Cannabis flos (draft monograph 3028)
  11. Provisional opinion on cannabidiol as a novel food — EFSA — February 2026 — EFSA Journal 2022;20(7):7322 — Statement on safety of cannabidiol as a novel food; data gaps reconfirmed February 2026
  12. Council Framework Decision 2004/757/JHA on illicit drug trafficking — Council of the European Union — Minimum criminal-law provisions; conduct for personal consumption falls outside its scope
  13. EU Drugs Strategy 2021–2025 — Council of the European Union — Council document ST 14178/20 — the framework preceding the 2026 strategy proposal
  14. Wet experiment gesloten coffeeshopketen — implementation documents — Ministry of Health, Welfare and Sport — 2025–2026 — Wet experiment gesloten coffeeshopketen, Stb. 2019/238; Besluit Stb. 2020/548; Startbesluit aanwijzing gemeenten
  15. Extension of the growers' waiting list until 7 April 2027 — Ministerial regulation — 21 March 2025 — Regeling van 21 maart 2025, Stcrt. 2025/9127 — verlenging wachtlijst telers
  16. THC/CBD monitor of coffeeshop cannabis and hashish — Trimbos-instituut — January 2026 — Trimbos-instituut — THC-monitor coffeeshopcannabis en hasjiesj 2024–2025 (TRI-41-030)
  17. Bericht der Bundesregierung zur Evaluation des Konsumcannabisgesetzes (KCanG) — Bundestagsdrucksache 21/3061 — Deutscher Bundestag — April 2026 — BT-Drucksache 21/3061
  18. Draft law on tighter controls on medical cannabis flower — Federal government — 14 July 2025 / 18 July 2026 — Medizinal-Cannabisgesetz (MedCanG), consolidated federal text; BMG amendment draft of 14 July 2025, cabinet decision 20 July 2026
  19. Cannabis Harm Reduction Associations — licensing framework — Authority on the Responsible Use of Cannabis (ARUC) — 2022–2026 — Authority on the Responsible Use of Cannabis Act, Chapter 620 of the Laws of Malta; ARUC Directive 1/2022 on Cannabis Harm Reduction Associations
  20. Law on private cultivation and consumption of cannabis — Government of Luxembourg — 2023 — Loi du 18 juillet 2023 modifiant la loi modifiée du 19 février 1973 (cannabis), Mémorial A n° 460 du 27 juillet 2023
  21. Amendment on personal cannabis use — approved 30 May 2025 — Chamber of Deputies of the Czech Republic — 2025 — Sněmovní tisk 663 — novela zákona o návykových látkách; přijato PS PČR 30. 5. 2025
  22. Approval of amendment on 3 July 2025 — Senate of the Czech Republic — 2025 — Zákon č. 270/2025 Sb. — schválen Senátem 3. 7. 2025, vyhlášen ve Sbírce zákonů
  23. Bundesgesetz über Cannabisprodukte — Vernehmlassung (Cannabis Products Act, public consultation) — Federal Department of Home Affairs (Switzerland) — 29 August – 1 December 2025 — Consultation 2025/59 — Bundesgesetz über Cannabisprodukte (CanPG), 29 August – 1 December 2025
  24. Ergebnisbericht Vernehmlassung Bundesgesetz über Cannabisprodukte — Federal Office of Public Health (BAG) — 24 June 2026 — Ergebnisbericht — consultation results report on the Cannabis Products Act, 24 June 2026
  25. Interim results (Basel, Lausanne and others) — Cantonal pilot programmes — March–May 2026 — Art. 8a BetmG — kantonale Pilotversuche (Weed Care Basel, Cann-L Lausanne, SCRIPT Zürich); Zwischenberichte 2026
  26. Final report on cannabis reform — London Drugs Commission — 28 May 2025 — London Drugs Commission — Final Report (Lord Falconer, chair), 28 May 2025
  27. First CBD isolate novel-food safety assessment — Food Standards Agency (FSA) — 26 June 2025 — Food Standards Agency — CBD business guidance and public list; first CBD isolate novel-food safety assessment (RP427), 26 June 2025
  28. Decreto-Legge 11 aprile 2025, n. 48 — misure urgenti in materia di sicurezza; converted into Legge 9 giugno 2025, n. 80 — Government of Italy — 11 April 2025 (DL) · 9 June 2025 (Law) — DL 48/2025 · Law 80/2025
  29. Circular on THC and driving — Ministries of Interior and Transport — 7 May 2025 — Circolare congiunta Ministero dell'Interno – MIT prot. 300/STRAD/1/0000024057.U del 7 maggio 2025
  30. Judgment on low-THC hemp flowers under the Tobacco Tax Act — Verwaltungsgerichtshof (Austria) — 21 November 2024 — Verwaltungsgerichtshof, Ro 2024/16/0006, judgment of 21 November 2024 (RIS case database)
  31. Cannabis Act (S.C. 2018, c. 16) and legislative review — Government of Canada — 2018–2026 — Cannabis Act, S.C. 2018, c. 16 (consolidated); Health Canada legislative review final report, March 2024
  32. National regulated cannabis programme — Instituto de Regulación y Control del Cannabis (IRCCA) — 2013–2026 — Ley N° 19.172 de 20 de diciembre de 2013; Decreto reglamentario 120/014; IRCCA — Informe anual 2025
  33. Schedules of Controlled Substances: Rescheduling of Marijuana — Notice of Proposed Rulemaking and administrative hearing — US Drug Enforcement Administration — Hearing 29 June – 15 July 2026 — Docket DEA-1362
  34. National Drug Threat Assessment 2025 — DEA — 28 May 2025 — DEA — 2025 National Drug Threat Assessment, DEA-DCT-DIR-018-25
  35. Local implementation guidance and enforcement notices — California / New York state agencies — October 2025 — California Department of Cannabis Control — laws and regulations (Title 4 CCR § 15000 et seq.); New York OCM adult-use enforcement guidance, October 2025
  36. Adult-use cannabis retail framework — official announcement — Commonwealth of Virginia — 16 June 2026 — Virginia Acts of Assembly — HB 2485 / SB 970 (2026 Reg. Session); Governor's announcement 16 June 2026
  37. Cannabis for Private Purposes Act — Government of South Africa — Assented 28 May 2024 — Cannabis for Private Purposes Act 7 of 2024, assented 28 May 2024; the substantive provisions still await a commencement proclamation
  38. Notification reclassifying cannabis flower as a controlled herb — Ministry of Public Health — 25 June 2025 — Notification of the Ministry of Public Health (No. 40) B.E. 2568 — cannabis flower as a controlled herb, Royal Gazette, 25 June 2025
  39. Announcement on transitional enforcement — Ministry of Public Health — 27 June 2025 — Royal Gazette — transitional enforcement arrangements for the cannabis flower controls, 27 June 2025
  40. Committee report on the Regulation of Cannabis Bill — Parliament of Victoria — 2025 — Parliament of Victoria, Legislative Council Legal and Social Issues Committee — Inquiry into the Regulation of Cannabis Bill 2023, final report
  41. Formal response to the Drug Summit recommendations — Government of New South Wales — 18 September 2025 — NSW Government Response to the NSW Drug Summit 2024 Communique, 18 September 2025
  42. Νόμος 5302/2026 — Restrictions on cannabis flower and licensing framework — Hellenic Republic — 21 May 2026 — Law 5302/2026, Government Gazette A' 78 of 21 May 2026 (National Printing House search portal)
  43. Consultative referendums of 9 June 2024 on medical cannabis and cultivation for personal use — State Election Commission of the Republic of Slovenia — Official referendum results; advisory outcome, implementing legislation pending
  44. Production and Trade in Illicit Drugs Act (ZPPPD), consolidated text — Uradni list Republike Slovenije — Statutory basis for cannabis control; personal use remains a minor offence
  45. Law No. 3528-IX regulating the circulation of cannabis plants for medical, industrial and scientific purposes — Verkhovna Rada of Ukraine — Adopted 21 December 2023; entered into force 16 August 2024
  46. Medical cannabis pilot programme, made permanent from 1 January 2022 — Retsinformation (Danish official legal information portal) — Prescription-only medical access; no adult-use framework
  47. Drugs Act of 24 February 1921 and implementing framework — Belgian Chamber of Representatives — Possession remains an offence; prosecution policy gives low priority to small quantities for adults
  48. Ley 17/1967 on narcotic drugs, consolidated text — Boletín Oficial del Estado — Private consumption is not a criminal offence; public consumption and possession are administrative offences
  49. Regulatory framework for standardised cannabis preparations for medical use — Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) — Hospital-dispensed medical access; no adult-use retail framework
  50. Decreto-Lei n.º 8/2019 on medicines and preparations based on the cannabis plant — Diário da República — Medical framework; personal possession decriminalised under Lei 30/2000
  51. General declaration of unconstitutionality on the prohibition of adult personal use (2021) — Suprema Corte de Justicia de la Nación — Judicial route to personal-use permits; no implementing legislation adopted
  52. Constitutional case law on the personal dose and the medical/industrial licensing framework — Corte Constitucional de Colombia — Personal dose protected; successive constitutional amendments for adult use were not adopted
  53. Loi n° 13-21 on the licensed use of cannabis for medical, pharmaceutical and industrial purposes — Secrétariat Général du Gouvernement (Bulletin Officiel) — Licensed cultivation supervised by ANRAC; recreational use remains prohibited
  54. Cannabis Legalisation and Control Bill and the 2020 binding referendum — New Zealand Parliament — Referendum of 17 October 2020 rejected the bill; the framework was not enacted
  55. Misuse of Drugs (Medicinal Cannabis) Regulations 2019 — New Zealand Legislation — Medicinal Cannabis Scheme; prescription-only access with product quality standards
  56. Law No. 178/2020 on the cultivation of cannabis for medical and industrial use — Republic of Lebanon — 2020 — Law No. 178/2020
  57. Draft decrees, technical annexes (GACP, GSP, GMP, track-and-trace) and digital licensing forms — Regulatory Authority for the Cultivation of Cannabis for Medical and Industrial Use — 2026 — Draft regulations (undated)
  58. Cannabis policy monographs and comparative analyses — EUDA — 2024–2026 — EUDA country profiles and comparative drug-policy monographs
  59. Public-health reviews of cannabis regulation — WHO Regional Office for Europe — 2024–2026

Appendix D. Register of monitored publications

This register lists every development published by the Foundation during the first year of monitoring. Each entry names the jurisdiction, the legal status at the closing date of 20 July 2026, the policy area, the official source and the chapter in which the development is discussed. The register is generated from the same dataset as the timeline, so the two cannot diverge.

Appendix E. Official legal documents by jurisdiction

Every legal claim in this white paper is traceable to a primary document issued by a legislature, government, court, regulator or official gazette. This appendix lists those documents per jurisdiction with the law, case or gazette reference and a direct link. Secondary reporting is not used as a legal source anywhere in this publication.